SCHEMBL4941215

SCHEMBL4941215

ClCCN(CCCl)CCOc1ccc(Nc2c3ccccc3nc3ccccc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
POLB P06746 2/20 0.61
RAD52 P43351 2/20 0.61
KDM4E B2RXH2 2/20 0.61
MAPT P10636 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
OPRM1 P35372 1/20 0.61
OPRD1 P41143 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SLC2A1 P11166 1/20 0.60
KDM1A O60341 12/20 0.54
GFER P55789 1/20 0.54
ATM Q13315 1/20 0.44
MEN1 O00255 1/20 0.43
GLA P06280 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4948317 0.93 POLB (0.58) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4940719 0.89 KDM1A (0.55) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4934135 0.87 KDM1A (0.48) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4938779 0.86 KDM1A (0.52) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4910290 0.82 TOP2A (0.55) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4933340 0.81 KDM1A (0.57) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4936777 0.81 KDM1A (0.46) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4933388 0.80 KDM1A (0.49) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL17154456 0.77 KDM1A (0.70) KMT2APOLBRAD52KDM4EMAPT
SCHEMBL4937726 0.77 KDM1A (0.46) KMT2APOLBRAD52KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176889-A1 9-anilinoacridine alkylating agents ACADEMIA SINICA (TW) 2008-07-24 US disclosed
US-20080176889-A1 9-anilinoacridine alkylating agents ACADEMIA SINICA (TW) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176889-A1 9-anilinoacridine alkylating agents BCL9, MCL1, BCL9L KMT2A 288/4885POLB 178/4885RAD52 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.